ICAM-1 as a biomarker of efficacy for oncolytic coxsackievirus A21 in patient-derived Ewing sarcoma models

Molecular Therapy: Oncology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles